A phase 1b clinical trial evaluating sifalimumab, an anti-IFN-α monoclonal antibody, shows target neutralisation of a type I IFN signature in blood of dermatomyositis and polymyositis patients (Q37465544)
Jump to navigation
Jump to search
scientific article published on 23 February 2013
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | A phase 1b clinical trial evaluating sifalimumab, an anti-IFN-α monoclonal antibody, shows target neutralisation of a type I IFN signature in blood of dermatomyositis and polymyositis patients |
scientific article published on 23 February 2013 |
Statements
1 reference
A phase 1b clinical trial evaluating sifalimumab, an anti-IFN-α monoclonal antibody, shows target neutralisation of a type I IFN signature in blood of dermatomyositis and polymyositis patients (English)
1 reference
Brandon W Higgs
1 reference
Wei Zhu
1 reference
Chris Morehouse
1 reference
Wendy I White
1 reference
Philip Brohawn
1 reference
Xiang Guo
1 reference
Marlon Rebelatto
1 reference
Chenxiong Le
1 reference
Anthony Amato
1 reference
David Fiorentino
1 reference
Steven A Greenberg
1 reference
Jorn Drappa
1 reference
Laura Richman
1 reference
Warren Greth
1 reference
Bahija Jallal
1 reference
Yihong Yao
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
Identifiers
1 reference